Royalty Pharma Plc (RPRX) — Cash Flow-to-Debt Ratio
Royalty Pharma Plc (RPRX) has a Cash Flow-to-Debt Ratio of 0.08x as of March 2026, meaning its operating cash flow of $760.54 Million could theoretically repay 0% of its total liabilities ($9.88 Billion) in one year. See RPRX FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Royalty Pharma Plc Cash Flow-to-Debt Ratio (2002–2025)
Historical debt coverage capacity for Royalty Pharma Plc across 14 annual periods. For the full cash flow conversion analysis, see Royalty Pharma Plc cash flow conversion.
Annual Cash Flow-to-Debt Ratio for Royalty Pharma Plc (2002–2025)
Year-by-year debt coverage analysis for Royalty Pharma Plc. Check Royalty Pharma Plc (RPRX) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.25x | $2.49 Billion | $9.91 Billion | ▼ -28.5% |
| 2024 | 0.35x | $2.77 Billion | $7.88 Billion | ▼ -25.9% |
| 2023 | 0.47x | $2.99 Billion | $6.30 Billion | ▲ +61.3% |
| 2022 | 0.29x | $2.14 Billion | $7.29 Billion | ▲ +6.0% |
| 2021 | 0.28x | $2.02 Billion | $7.27 Billion | ▼ -16.4% |
| 2020 | 0.33x | $2.03 Billion | $6.12 Billion | ▲ +25.7% |
| 2019 | 0.26x | $1.67 Billion | $6.31 Billion | ▲ +11.3% |
| 2018 | 0.24x | $1.62 Billion | $6.82 Billion | ▲ +15.5% |
| 2017 | 0.21x | $1.42 Billion | $6.90 Billion | ▲ +8039.6% |
| 2016 | 0.00x | $-15.58 Million | $6.02 Billion | ▲ +37.5% |
| 2015 | 0.00x | $-25.33 Million | $6.12 Billion | ▲ +100.0% |
| 2014 | -10.03x | $-29.33 Million | $2.92 Million | ▼ -148.7% |
| 2003 | 20.61x | $11.15 Million | $541.00K | ▲ +26.7% |
| 2002 | 16.27x | $8.45 Million | $519.00K | — |